FDA Denies Outlook’s Wet AMD Bid, Issues Complete Response Letter

FDA Denies Outlook’s Wet AMD Bid, Issues Complete Response Letter

Submitted by admin on August 30, 2023 - 11:01am
Source: 
BioSpace
News Tags: 
Outlook Therapeutics
ONS-5010
wet age-related macular degeneration
FDA
Headline: 
FDA Denies Outlook’s Wet AMD Bid, Issues Complete Response Letter
snippet: 

The FDA on Wednesday rejected Outlook Therapeutics’ investigational ophthalmic bevacizumab solution ONS-5010, which the company was proposing as a treatment for wet age-related macular degeneration.

Do Not Allow Advertisers to Use My Personal information